Please enable JavaScript to continue using this application.

Compare $GNLX vs $INO | Chartloom

Compare

$GNLX vs $INO

Genelux Corp · Inovio Pharmaceuticals Inc

GNLX

Genelux Corp

INO

Inovio Pharmaceuticals Inc

Compare $GNLX vs $INO

Comparing Genelux Corp and Inovio Pharmaceuticals Inc

GNLXGenelux Corp

INOInovio Pharmaceuticals Inc

GNLXGenelux Corp

Market cap

$115M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-43.7%

52W performance

-46.1%

FCF yield

-25.0%

INOInovio Pharmaceuticals Inc

Market cap

$95M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

2.48x

Rev growth (TTM)

-100.0%

YTD performance

-32.0%

52W performance

-55.1%

FCF yield

-85.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GNLX

INO

Detailed metrics comparison

GNLX

Genelux Corp

INO

Inovio Pharmaceuticals Inc

Market Cap

GNLX$115M

INO$95M

Enterprise Value

GNLX$106M

INO$63M

Price

GNLX$2.56

INO$1.15

P/E Ratio

GNLXN/A

INON/A

P/S Ratio

GNLX14,348.80x

INO423.69x

EV/Sales

GNLX13,200.80x

INO312.32x

EV/EBITDA

GNLX0.00x

INO0.00x

P/B Ratio

GNLX7.19x

INO27.44x

P/FCF Ratio

GNLXN/A

INON/A

EV/FCF

GNLX-3.68x

INO-0.78x

PEG Ratio

GNLXN/A

INON/A

Forward P/E (NTM)

GNLXN/A

INON/A

Forward P/S (NTM)

GNLXN/A

INO2.48x

Revenue (TTM)

GNLX$8K

INO$0

Revenue Growth (YoY)

GNLXN/A

INO-100.0%

Forward Rev Growth

GNLX551.6%

INO7491.0%

Gross Margin (TTM)

GNLX0.0%

INO58.9%

Operating Margin (TTM)

GNLX0.0%

INO0.0%

EBITDA Margin (TTM)

GNLX-453500.0%

INO0.0%

Net Margin (TTM)

GNLX-444950.0%

INO0.0%

FCF Margin (TTM)

GNLX-358537.5%

INON/A

Net Income (TTM)

GNLX$-36M

INO$-67M

FCF (TTM)

GNLX$-29M

INO$-81M

EPS (TTM)

GNLX-$0.79

INO-$0.83

ROE (TTM)

GNLX-20585.0%

INO-19050.0%

ROA (TTM)

GNLX-13879.0%

INO-11105.0%

ROIC (TTM)

GNLX-20585.0%

INO-19050.0%

Cash

GNLX$9M

INO$32M

Debt

GNLX$0

INO$0

Net Cash/Debt

GNLX$9M

INO$32M

Current Ratio (TTM)

GNLX2.39x

INO1.00x

Quick Ratio (TTM)

GNLX2.33x

INO0.92x

Debt/Equity (TTM)

GNLX0.00x

INO0.00x

Debt/Assets (TTM)

GNLX0.0%

INO0.0%

Interest Coverage (TTM)

GNLXN/A

INON/A

Net Debt/EBITDA (TTM)

GNLX0.00x

INO0.00x

Beta

GNLX0.56

INO1.68

52W Performance

GNLX-46.1%

INO-55.1%

YTD Performance

GNLX-43.7%

INO-32.0%

% from 52W High

GNLX-70.0%

INO-57.7%

% from 52W Low

GNLX11.8%

INO104.2%

Asset Turnover (TTM)

GNLX0.00x

INO0.00x

FCF Yield (TTM)

GNLX-25.0%

INO-85.4%

Earnings Yield (TTM)

GNLX-31.0%

INO-71.3%

Dividend Yield (TTM)

GNLXN/A

INON/A

Rule of 40

GNLX-358,537.5

INO-100.0

EV/GP/RG

GNLXN/A

INON/A

Ticker research

View GNLX research View INO research

Metric	GNLX Genelux Corp	INO Inovio Pharmaceuticals Inc
Market & Valuation
Market Cap	$115M	$95M
Enterprise Value	$106M	$63M
Price	$2.56	$1.15
P/E Ratio	N/A	N/A
P/S Ratio	14,348.80x	423.69x
EV/Sales	13,200.80x	312.32x
EV/EBITDA	0.00x	0.00x
P/B Ratio	7.19x	27.44x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.68x	-0.78x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	2.48x
Revenue & Growth
Revenue (TTM)	$8K	$0
Revenue Growth (YoY)	N/A	-100.0%
Forward Rev Growth	551.6%	7491.0%
Profitability
Gross Margin (TTM)	0.0%	58.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-453500.0%	0.0%
Net Margin (TTM)	-444950.0%	0.0%
FCF Margin (TTM)	-358537.5%	N/A
Net Income (TTM)	$-36M	$-67M
FCF (TTM)	$-29M	$-81M
EPS (TTM)	-$0.79	-$0.83
ROE (TTM)	-20585.0%	-19050.0%
ROA (TTM)	-13879.0%	-11105.0%
ROIC (TTM)	-20585.0%	-19050.0%
Financial Health
Cash	$9M	$32M
Debt	$0	$0
Net Cash/Debt	$9M	$32M
Current Ratio (TTM)	2.39x	1.00x
Quick Ratio (TTM)	2.33x	0.92x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.56	1.68
52W Performance	-46.1%	-55.1%
YTD Performance	-43.7%	-32.0%
% from 52W High	-70.0%	-57.7%
% from 52W Low	11.8%	104.2%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-25.0%	-85.4%
Earnings Yield (TTM)	-31.0%	-71.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-358,537.5	-100.0
EV/GP/RG	N/A	N/A
Ticker research	View GNLX research	View INO research

Valuation

P/S Ratio

INO

423.69x

GNLX

14,348.80x

EV/FCF

GNLX

-3.68x

INO

-0.78x

Growth & revenue

Revenue Growth TTM

INO

-100.0%

Forward Revenue Growth

INO

7491.0%

GNLX

551.6%

Profitability & performance

Gross Margin

INO

58.9%

GNLX

0.0%

ROE

INO

-19050.0%

GNLX

-20585.0%

FCF Yield %

GNLX

-25.0%

INO

-85.4%

52-Week Performance

GNLX

-46.1%

INO

-55.1%

Detailed metrics comparison

GNLX

Genelux Corp

INO

Inovio Pharmaceuticals Inc

Market Cap

GNLX$115M

INO$95M

Enterprise Value

GNLX$106M

INO$63M

Price

GNLX$2.56

INO$1.15

P/E Ratio

GNLXN/A

INON/A

P/S Ratio

GNLX14,348.80x

INO423.69x

EV/Sales

GNLX13,200.80x

INO312.32x

EV/EBITDA

GNLX0.00x

INO0.00x

P/B Ratio

GNLX7.19x

INO27.44x

P/FCF Ratio

GNLXN/A

INON/A

EV/FCF

GNLX-3.68x

INO-0.78x

PEG Ratio

GNLXN/A

INON/A

Forward P/E (NTM)

GNLXN/A

INON/A

Forward P/S (NTM)

GNLXN/A

INO2.48x

Revenue (TTM)

GNLX$8K

INO$0

Revenue Growth (YoY)

GNLXN/A

INO-100.0%

Forward Rev Growth

GNLX551.6%

INO7491.0%

Gross Margin (TTM)

GNLX0.0%

INO58.9%

Operating Margin (TTM)

GNLX0.0%

INO0.0%

EBITDA Margin (TTM)

GNLX-453500.0%

INO0.0%

Net Margin (TTM)

GNLX-444950.0%

INO0.0%

FCF Margin (TTM)

GNLX-358537.5%

INON/A

Net Income (TTM)

GNLX$-36M

INO$-67M

FCF (TTM)

GNLX$-29M

INO$-81M

EPS (TTM)

GNLX-$0.79

INO-$0.83

ROE (TTM)

GNLX-20585.0%

INO-19050.0%

ROA (TTM)

GNLX-13879.0%

INO-11105.0%

ROIC (TTM)

GNLX-20585.0%

INO-19050.0%

Cash

GNLX$9M

INO$32M

Debt

GNLX$0

INO$0

Net Cash/Debt

GNLX$9M

INO$32M

Current Ratio (TTM)

GNLX2.39x

INO1.00x

Quick Ratio (TTM)

GNLX2.33x

INO0.92x

Debt/Equity (TTM)

GNLX0.00x

INO0.00x

Debt/Assets (TTM)

GNLX0.0%

INO0.0%

Interest Coverage (TTM)

GNLXN/A

INON/A

Net Debt/EBITDA (TTM)

GNLX0.00x

INO0.00x

Beta

GNLX0.56

INO1.68

52W Performance

GNLX-46.1%

INO-55.1%

YTD Performance

GNLX-43.7%

INO-32.0%

% from 52W High

GNLX-70.0%

INO-57.7%

% from 52W Low

GNLX11.8%

INO104.2%

Asset Turnover (TTM)

GNLX0.00x

INO0.00x

FCF Yield (TTM)

GNLX-25.0%

INO-85.4%

Earnings Yield (TTM)

GNLX-31.0%

INO-71.3%

Dividend Yield (TTM)

GNLXN/A

INON/A

Rule of 40

GNLX-358,537.5

INO-100.0

EV/GP/RG

GNLXN/A

INON/A

Ticker research

View GNLX research View INO research

Metric	GNLX Genelux Corp	INO Inovio Pharmaceuticals Inc
Market & Valuation
Market Cap	$115M	$95M
Enterprise Value	$106M	$63M
Price	$2.56	$1.15
P/E Ratio	N/A	N/A
P/S Ratio	14,348.80x	423.69x
EV/Sales	13,200.80x	312.32x
EV/EBITDA	0.00x	0.00x
P/B Ratio	7.19x	27.44x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.68x	-0.78x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	2.48x
Revenue & Growth
Revenue (TTM)	$8K	$0
Revenue Growth (YoY)	N/A	-100.0%
Forward Rev Growth	551.6%	7491.0%
Profitability
Gross Margin (TTM)	0.0%	58.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-453500.0%	0.0%
Net Margin (TTM)	-444950.0%	0.0%
FCF Margin (TTM)	-358537.5%	N/A
Net Income (TTM)	$-36M	$-67M
FCF (TTM)	$-29M	$-81M
EPS (TTM)	-$0.79	-$0.83
ROE (TTM)	-20585.0%	-19050.0%
ROA (TTM)	-13879.0%	-11105.0%
ROIC (TTM)	-20585.0%	-19050.0%
Financial Health
Cash	$9M	$32M
Debt	$0	$0
Net Cash/Debt	$9M	$32M
Current Ratio (TTM)	2.39x	1.00x
Quick Ratio (TTM)	2.33x	0.92x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.56	1.68
52W Performance	-46.1%	-55.1%
YTD Performance	-43.7%	-32.0%
% from 52W High	-70.0%	-57.7%
% from 52W Low	11.8%	104.2%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-25.0%	-85.4%
Earnings Yield (TTM)	-31.0%	-71.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-358,537.5	-100.0
EV/GP/RG	N/A	N/A
Ticker research	View GNLX research	View INO research